NASDAQ : SCNI
Scinai Immunotherapeutics Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 0.4716 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 268.82K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 268,822 |
| Enterprise Value | 1.19M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 570,022 |
| Shares Change (YoY) | +303.74% |
| Shares Change (QoQ) | +198.64% |
| Owned by Insiders (%) | 14.26% |
| Owned by Institutions (%) | 3.44% |
| Float | 488,726 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.18 |
| Forward PS | n/a |
| PB Ratio | 0.04 |
| P/TBV Ratio | 0.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.56 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.54 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.53% |
| Return on Assets (ROA) | -36.15% |
| Return on Invested Capital (ROIC) | -41.10% |
| Return on Capital Employed (ROCE) | -56.16% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | $33,044 |
| Profits Per Employee | -$57,756 |
| Employee Count | 45 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.13 |
| 52-Week Price Change | -96.75% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 4.46 |
| Relative Strength Index (RSI) | 22.88 |
| Average Volume (20 Days) | 3,431,187 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 179,643 |
| Short Previous Month | 19,900 |
| Short % of Shares Out | 13.53% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.49M |
| Gross Profit | -3.75M |
| Operating Income | -8.39M |
| Pretax Income | -2.60M |
| Net Income | -2.60M |
| EBITDA | -6.64M |
| EBIT | -8.39M |
| Loss Per Share | -$13.94 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.65M |
| Total Debt | 3.58M |
| Net Cash | -926,000 |
| Net Cash Per Share | -$1.62 |
| Equity (Book Value) | 11.73M |
| Book Value Per Share | 10.71 |
| Working Capital | 1.26M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.38M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 1.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -7.50M |
| FCF Per Share | -$13.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | -252.32% |
| Operating Margin | -564.36% |
| Pretax Margin | -174.78% |
| Profit Margin | -174.78% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -303.74% |
| Shareholder Yield | -303.74% |
| Earnings Yield | -2,956.01% |
| FCF Yield | -2,791.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 118.93% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.27 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |